CRP and coronary artery disorder: These dose–response relationships between the amount of weight loss and treatment benefits were observed when body weight change was analyzed both as an ordinal (Fig. 3) and as a continuous variable, after adjusting for age, sex, NYHA class, history of atrial fibrillation and coronary artery disease, baseline CRP and NTproBNP at baseline (Table 2).